Home Print this page Email this page
Users Online: 319
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2016  |  Volume : 4  |  Issue : 1  |  Page : 52-55

The hypotensive and uricosuric effect of valsartan compared to losartan in gout patients


1 Department of Clinical and Hospital Pharmacy, College of Pharmacy, Taibah University, Madinah, Saudi Arabia
2 Department of Applied Pharmaceutical Sciences, College of Pharmacy, Isra University, Amman, Jordan, USA
3 Department of Internal Medicine, St. Vincent Charity Medical Center, Cleveland, OH, USA

Correspondence Address:
Prof. Anas Bahnassi
Department of Clinical and Hospital Pharmacy, College of Pharmacy, Taibah University, P. O. Box 30117, Madinah 41477
Saudi Arabia
Login to access the Email id


DOI: 10.4103/1658-600X.173833

Rights and Permissions

Objective: Our objective was to investigate the possible relationship between previous or concurrent use of losartan or valsartan and gout in newly diagnosed patients. Materials and Methods: Thirty-two newly-diagnosed gout patients, whose blood pressure was controlled using losartan for at least 3 months were included. The study was divided into 3 stages; stage I where patients were controlled for 3 months using losartan (50 mg/day), stage II - where patients were switched from losartan to valsartan (80 mg/day) with their blood pressure controlled and maintained for another 3 months using valsartan instead of losartan and stage III - where patients were switched back to losartan (50 mg/day). All changes in clinical and biochemical parameters were reported. Results: There were no significant changes in biochemical parameters such as liver enzymes, serum levels of creatinine, sodium and bicarbonate. Serum levels of potassium and uric acid were elevated. Valsartan significantly increased potassium and uric acid levels at the end of stage II (P = 0.024). Since these adverse effects did not disappear after changing back to losartan at the end of stage III, we performed an additional 3-month follow-up stage. The subjects required a period of 6 months to return to levels seen at the end of stage I. Conclusion: Losartan showed a slightly higher hypotensive effect than valsartan in patients newly diagnosed with gout. It also resulted in lower uric acid levels.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed6200    
    Printed70    
    Emailed0    
    PDF Downloaded278    
    Comments [Add]    

Recommend this journal